Categories
Change Password!
Reset Password!
Using high-dose coenzyme-Q10 for six months effectively alleviates liver steatosis and improves vascular and heart function in MASLD-affected people.
In a new randomized controlled trial published in "Cardiovascular Diabetology", coenzyme-Q10 (lipid-soluble quinone with a central benzoquinone ring) demonstrated significant clinical benefits for patients with metabolic-dysfunction associated steatotic liver disease (MASLD, or non-alcoholic fatty liver disease [NAFLD]). This study by Emmanouil Vrentzos and other researchers assessed whether six-month supplementation with coenzyme-Q10 could boost vascular, endothelial, and myocardial health in MASLD-affected patients.
Researchers conducted a 6-month double-blind trial with 60 MASLD patients randomized to receive either 240 mg of coenzyme-Q10 daily or a placebo. Key measures included sublingual vessel imaging via sideview darkfield technique, pulse-wave velocity, flow-intervened dilation of brachial artery, left ventricular global longitudinal strain, coronary flow reserve of the left anterior descending coronary artery, and liver steatosis estimation.
When compared to the baseline, patients taking coenzyme-Q10 reported the following improvements six months after treatment:
No vital changes were witnessed in the placebo group. In participants on coenzyme-Q10, a decrease in the controlled attenuation parameter score was positively linked with decreased perfused boundary region and pulse wave velocity, and inversely linked to elevation in coronary flow reserve and flow-intervened dilation. Thus, six months of high-dose coenzyme-Q10 successfully lowers liver steatosis and enhances vascular, endothelial, and left ventricle myocardial function in MASLD people, showing remarkable betterments in both micro- and macro-vascular function.
Cardiovascular Diabetology
Six-month supplementation with high dose coenzyme Q10 improves liver steatosis, endothelial, vascular and myocardial function in patients with metabolic-dysfunction associated steatotic liver disease: a randomized double-blind, placebo-controlled trial
Emmanouil Vrentzos et al.
Comments (0)